Sex-Gender Differences in the Effectiveness of Treatment of Irritable Bowel Syndrome: A Systematic Review

References

• Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71–80. doi:10.2147/CLEP.S40245
   PubMed Web of Science ®Google Scholar
• Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313(9):949–958. doi:10.1001/jama.2015.0954
   PubMed Web of Science ®Google Scholar
• Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123(6):2108–2131.
   PubMed Web of Science ®Google Scholar
• Kim YS, Kim N. Sex-gender differences in irritable bowel syndrome. J Neurogastroenterol Motil. 2018;24(4):544–558. doi:10.5056/jnm18082
   PubMed Web of Science ®Google Scholar
• Lee OY, Mayer EA, Schmulson M, Chang L, Naliboff B. Gender-related differences in IBS symptoms. Am J Gastroenterol. 2001;96(7):2184–2193. doi:10.1111/j.1572-0241.2001.03961.x
   PubMed Web of Science ®Google Scholar
• Chang L, Heitkemper MM. Gender differences in irritable bowel syndrome. Gastroenterology. 2002;123(5):1686–1701. doi:10.1053/gast.2002.36603
   PubMed Web of Science ®Google Scholar
• Vemuri R, Sylvia KE, Klein SL, et al. The microgenderome revealed: sex differences in bidirectional interactions between the microbiota, hormones, immunity and disease susceptibility. Semin Immunopathol. 2019;41(2):265–275. doi:10.1007/s00281-018-0716-7
   PubMed Web of Science ®Google Scholar
• Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48(3):143–157. doi:10.2165/00003088-200948030-00001
   PubMed Web of Science ®Google Scholar
• Hungin AP, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther. 2005;21(11):1365–1375. doi:10.1111/j.1365-2036.2005.02463.x
   PubMed Web of Science ®Google Scholar
• Lagro-Janssen T. Gender, equality and medicine 2013:48.
   Google Scholar
• NIoH N. Quality assessment of controlled intervention studies. Systematic evidence reviews and clinical practice guidelines; 2014. Available from: www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed February 6, 2021.
   Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928. doi:10.1136/bmj.d5928
   PubMed Web of Science ®Google Scholar
• Kennedy TM, Chalder T, McCrone P, et al. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial. Health Technol Assess. 2006;10(19):iii–iv, ix–x, 1–67. doi:10.3310/hta10190
   PubMed Web of Science ®Google Scholar
• George AM, Meyers NL, Hickling RI. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome–multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting. Aliment Pharmacol Ther. 2008;27(9):830–837. doi:10.1111/j.1365-2036.2008.03649.x
   PubMed Web of Science ®Google Scholar
• Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A Phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion. 2008;77(3–4):225–235. doi:10.1159/000150632
   PubMed Web of Science ®Google Scholar
• Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999;13(9):1149–1159. doi:10.1046/j.1365-2036.1999.00610.x
   PubMed Web of Science ®Google Scholar
• Bardhan KD, Bodemar G, Geldof H, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2000;14(1):23–34. doi:10.1046/j.1365-2036.2000.00684.x
   PubMed Web of Science ®Google Scholar
• Tack J, Schumacher K, Tonini G, Scartoni S, Capriati A, Maggi CA. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS. Gut. 2017;66(8):1403–1413. doi:10.1136/gutjnl-2015-310683
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412–419. doi:10.1111/j.1572-0241.2003.07234.x
   PubMed Web of Science ®Google Scholar
• Mangel AW, Chaturvedi P. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion. 2008;78(4):180–186. doi:10.1159/000185719
   PubMed Web of Science ®Google Scholar
• Lacy BE, Harris LA, Chang L, et al. Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of Phase III trials. Therap Adv Gastroenterol. 2019;12:1756284819841290. doi:10.1177/1756284819841290
   Web of Science ®Google Scholar
• Farnam A, Somi MH, Farhang S, Mahdavi N, Ali Besharat M. The therapeutic effect of adding emotional awareness training to standard medical treatment for irritable bowel syndrome: a randomized clinical trial. J Psychiatr Pract. 2014;20(1):3–11. doi:10.1097/01.pra.0000442934.38704.3a
   PubMed Web of Science ®Google Scholar
• Tack JF, Miner PB, Fischer L, Harris MS. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;34(8):868–877. doi:10.1111/j.1365-2036.2011.04818.x
   PubMed Web of Science ®Google Scholar
• Hong YS, Hong KS, Park MH, et al. Metabonomic understanding of probiotic effects in humans with irritable bowel syndrome. J Clin Gastroenterol. 2011;45(5):415–425. doi:10.1097/MCG.0b013e318207f76c
   PubMed Web of Science ®Google Scholar
• Womersley K, Ripullone K, Peters SA, Woodward M. Covid-19: male disadvantage highlights the importance of sex disaggregated data. BMJ. 2020;370:m2870. doi:10.1136/bmj.m2870
   PubMed Web of Science ®Google Scholar
• Bellini M, Usai-Satta P, Bove A, et al. Chronic constipation diagnosis and treatment evaluation: the “CHRO.CO.DI.T.E.” study. BMC Gastroenterol. 2017;17(1):11. doi:10.1186/s12876-016-0556-7
   PubMed Web of Science ®Google Scholar
• Bellucci F, Buéno L, Bugianesi R, et al. Gender-related differential effect of tachykinin NK2 receptor-mediated visceral hyperalgesia in guinea pig colon. Br J Pharmacol. 2016;173(8):1329–1338. doi:10.1111/bph.13427
   PubMed Web of Science ®Google Scholar
• Nee J, Salley K, Ludwig AG, et al. Randomized clinical trial: crofelemer treatment in women with diarrhea-predominant irritable bowel syndrome. Clin Transl Gastroenterol. 2019;10(12):e00110. doi:10.14309/ctg.0000000000000110
   PubMed Web of Science ®Google Scholar
• Ghoshal UC, Shukla R, Ghoshal U. Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy. Gut Liver. 2017;11(2):196–208. doi:10.5009/gnl16126
   PubMed Web of Science ®Google Scholar
• Mulak A, Taché Y. Sex difference in irritable bowel syndrome: do gonadal hormones play a role? Gastroenterol Pol. 2010;17(2):89–97.
   PubMedGoogle Scholar
• Mattila AK, Kronholm E, Jula A, et al. Alexithymia and somatization in general population. Psychosom Med. 2008;70(6):716–722. doi:10.1097/PSY.0b013e31816ffc39
   PubMed Web of Science ®Google Scholar
• Steinweg DL, Dallas AP, Rea WS. Fibromyalgia: unspeakable suffering, a prevalence study of alexithymia. Psychosomatics. 2011;52(3):255–262. doi:10.1016/j.psym.2010.12.022
   PubMed Web of Science ®Google Scholar
• Salminen JK, Saarijärvi S, Äärelä E, Toikka T, Kauhanen J. Prevalence of alexithymia and its association with sociodemographic variables in the general population of finland. J Psychosom Res. 1999;46(1):75–82. doi:10.1016/S0022-3999(98)00053-1
   PubMed Web of Science ®Google Scholar
• Brown LA, Wiley JF, Wolitzky-Taylor K, et al. Changes in self-efficacy and outcome expectancy as predictors of anxiety outcomes from the CALM study. Depress Anxiety. 2014;31(8):678–689. doi:10.1002/da.22256
   PubMed Web of Science ®Google Scholar
• Mosińska P, Storr M, Fichna J. The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective. Therap Adv Gastroenterol. 2015;8(5):278–284. doi:10.1177/1756283X15587866
   PubMed Web of Science ®Google Scholar
• Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126(3):693–702. doi:10.1053/j.gastro.2003.11.055
   PubMed Web of Science ®Google Scholar
• Preston K, Krumian R, Hattner J, de Montigny D, Stewart M, Gaddam S. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. Benef Microbes. 2018;9(5):697–706. doi:10.3920/BM2017.0105
   PubMed Web of Science ®Google Scholar
• Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167. doi:10.1136/bmj.326.7400.1167
   PubMed Web of Science ®Google Scholar